A new three-drug combination therapy significantly extended survival for patients with metastatic colorectal cancer and the BRAF V600E mutation, doubling life expectancy in a late-stage trial. CU Cancer Center’s Christopher Lieu, MD, a national leader in GI oncology, called the findings “very impactful,” stating the treatment now represents the new standard of care.
CU Anschutz
Anschutz Cancer Pavilion
1665 North Aurora Court
2004
Aurora, CO 80045